ReviewFrontiers in immunology2020
Autoimmunity in Segmental Vitiligo.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025).The Journal of dermatology · 2026Guideline
- Demographic factors associated with response to topical Jak inhibitors in a diverse vitiligo cohort.JID innovations : skin science from molecules to population health · 2026Article
- Segmental Vitiligo and Somatic Mosaicism: From Pathogenesis to Therapeutics.Annals of dermatology · 2026Review
- Vitiligo.Nature reviews. Disease primers · 2025Review
- Article
- Segmental Vitiligo: Rapid Spread From a Halo Nevus.Cureus · 2025Article
- Candidate approaches for predicting vitiligo recurrence: an effective model and biomarkers.Frontiers in immunology · 2025Article
- Vitiligo: From Pathogenesis to Treatment.Journal of clinical medicine · 2024Review
- Circadian clock gene expression and polymorphism in non-segmental vitiligo.Molecular biology reports · 2024Article
- A Mendelian randomization study on the causal effects of circulating cytokines on the risk of vitiligo.Frontiers in medicine · 2024Article
- Segmental vitiligo distribution follows the underlying arterial blood supply territory: a hypothesis based on anatomo-clinical, pathological and physio-pathological studies.Frontiers in medicine · 2024Article
- Vitiligo and insulin resistance as a component of metabolic syndrome: an analysis.Postepy dermatologii i alergologii · 2023Review
- Varicella-zoster virus in actively spreading segmental vitiligo skin: Pathological, immunochemical, and ultrastructural findings (a first and preliminary study).Pigment cell & melanoma research · 2023Article
- Co-occurrence of linear scleroderma en coup de sabre and segmental vitiligo on the face.BMJ case reports · 2022Article
- Circulatory levels of alarmins in patients with non-segmental vitiligo: Potential biomarkers for disease diagnosis and activity/severity assessment.Frontiers in immunology · 2022Article
- Immunometabolism in the pathogenesis of vitiligo.Frontiers in immunology · 2022Review
- Epidemiology of Vitiligo - A Dual Population-Based Approach.Clinical epidemiology · 2021Article
- A new approach using a numerical diagnostic criterion for vitiligo diagnosis with HMB-45 and Melan-A staining.International journal of clinical and experimental pathology · 2021Article
- Plant-Derived Compounds as Promising Therapeutics for Vitiligo.Frontiers in pharmacology · 2021Review
- Fatty acid-binding protein 4 circulating levels in non-segmental vitiligo.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The autoimmune basis of segmental vitiligo (SV) has only recently been recognized. Systemic autoimmune diseases are less frequently associated compared to non-segmental vitiligo (NSV), but localized skin disorders - in particular linear morphea - have been repeatedly observed in patients with SV. The inflammatory response is documented on a clinical level with cases displaying erythematous borders or a hypochromic stage, on a histopathological level with predominantly CD8 lymphocytes migrating toward the basal layer and by flow cytometry demonstrating the antimelanocyte specificity of these cytotoxic T cells. The increased risk for halo naevi and NSV in these patients further underline the immune-mediated mechanisms of SV. Nonetheless, the localized and unique distribution pattern points to somatic mosaicism. This places SV in a category of similar diseases such as lichen striatus, blaschkitis, linear lupus erythematosus, and linear scleroderma where an immune reaction against genetically mutated skin cells is believed to be the underlying cause. All these disorders are characterized by a young age of onset, a temporary disease activity with spontaneous resolution, limited response to treatment, and often long-term sequelae. Although challenging, genetic research proving this genetic mosaicism could offer crucial insights into the pathogenesis of both segmental and non-segmental vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.